Aquipta Special Precautions

Serious hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial oedema, have been reported with use of AQUIPTA (see Adverse Reactions). Most serious reactions have occurred within 24 hours of first use, however, some hypersensitivity reactions can occur days after administration. Patients should be warned about the symptoms associated with hypersensitivity. If a hypersensitivity reaction occurs, discontinue AQUIPTA and institute appropriate therapy.
Hepatic impairment: Atogepant is not recommended in patients with severe hepatic impairment (see Dosage & Administration).
Excipients with known effect: Atogepant (Aquipta) 10 mg tablets contain less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Atogepant (Aquipta) 60 mg tablets contain 31.5 mg sodium per tablet, equivalent to 1.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Effects on ability to drive and use machines: Atogepant has no or negligible influence on the ability to drive and use machines. However, it may cause somnolence in some patients. Patients should exercise caution before driving or using machinery until they are reasonably certain that atogepant does not adversely affect performance.